Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Ligand Licenses Drug To Chiva

by Rick Mullin
October 16, 2011 | A version of this story appeared in Volume 89, Issue 42

Ligand Pharmaceuticals and Chiva Pharmaceuticals, a Chinese biopharmaceutical firm, have entered a global licensing agreement for Fablyn, a selective estrogen receptor modulator approved in the European Union in 2009 for the treatment of osteoporosis in postmenopausal women. Under the terms of the agreement, Ligand will receive $4 million in licensing payments over the next eight months as well as unspecified milestone and royalty payments for worldwide sales of Fablyn. Discovered through a research collaboration between Ligand and Pfizer, Fablyn was developed by Pfizer after approval in the EU. With the acquisition of Wyeth, Pfizer acquired a similar program for osteoporosis, after which Ligand obtained full ownership of Fablyn.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.